Eiger BioPharmaceuticals, Inc.

Eiger’s confirmed liquidation plan is effective, and its liquidating trust continues to administer claims and distributions. The claims deadline order Dkt. 956 extends the deadline to object to claims to December 17, 2026, at 5:00 p.m. Central Time.

Eiger BioPharmaceuticals is in post-confirmation liquidation: its fifth amended joint plan was confirmed on September 5, 2024, and became effective on September 30, 2024. The confirmation order Dkt. 639 provides for a plan administrator and liquidating trustee to carry out the wind-down, and the effective-date notice Dkt. 685 records the plan’s effectiveness.

Eiger filed for Chapter 11 on April 1, 2024, after clinical and financial setbacks, including the discontinuation of its Phase 3 peginterferon lambda trial because of safety concerns. Its first-day declaration Dkt. 19 reported approximately $9.9 million in cash at filing and a $75 million loss in 2023. Funded debt at the petition date totaled $41,685,030.30 across three instruments, with the balance outstanding under Innovatus’s Term A loan, according to the declaration’s debt table.

The Chapter 11 process centered on asset sales. As the confirmation order Dkt. 639 records, Eiger completed sales of the Zokinvy assets to Sentynl Therapeutics and the Avexitide assets to Amylyx Pharmaceuticals before confirmation. The plan also incorporated a settlement among the debtors, prepetition secured parties and equity committee.

In its report for the quarter ended September 30, 2026 Dkt. 964, the liquidating trust reported cumulative plan payments of $197,372 on priority claims, $3,636,753.01 to general unsecured creditors and $5,750,000 to equity interests. Claims administration continues: the October 13, 2026 order Dkt. 956 extended the claims-objection deadline to December 17, 2026, at 5:00 p.m. Central Time.